Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model

Journal of Neuro-Oncology

Volumn 98, Issue 1, 2010, Pages 11-19

  Demestre, Maria ^a   Herzberg, Jan ^a   Holtkamp, Nikola ^b   Hagel, Christian ^a   Reuss, David ^c   Friedrich, Reinhard E ^a   Kluwe, Lan ^a   Von Deimling, Andreas ^c   Mautner, Victor F ^a   Kurtz, Andreas ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Glivec; Imatinib mesylate; Neurofibromatosis; Plexiform neurofibromas; Xenografts

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEUROFIBROMA; NONHUMAN; PLEXIFORM NEUROFIBROMA; PROTEIN EXPRESSION; SCHWANN CELL; TUMOR MODEL; TUMOR VOLUME; TUMOR XENOGRAFT;

ADOLESCENT; ADULT; ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SIZE; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NEUROFIBROMA, PLEXIFORM; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; S100 PROTEINS; SCHWANN CELLS; YOUNG ADULT;

EID: 77953617933     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-0049-4     Document Type: Article

References (16)

1. JH Tonsgard SM Kwak MP Short AH Dachman 1998 CT imaging in adults with neurofibromatosis-1: frequent asymptomatic plexiform lesions Neurology 50 6 1755 1760 1:STN:280:DyaK1c3psFCrsg%3D%3D 9633723
2. Mautner VF, Hartmann M, Kluwe L, Friedrich RE, Funsterer C (2006) MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1. Neuroradiology 48(3):160-165. Epub 2006 Jan 24
3. T Tucker JM Friedman RE Friedrich R Wenzel C Funsterer VF Mautner 2008 Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas J Med Genet 17 17
4. DG Evans ME Baser J McGaughran S Sharif E Howard A Moran 2002 Malignant peripheral nerve sheath tumours in neurofibromatosis 1 J Med Genet 39 5 311 314 10.1136/jmg.39.5.311 1:STN:280:DC%2BD383nt1Wquw%3D%3D 12011145
5. BJ Druker F Guilhot SG O'Brien I Gathmann H Kantarjian N Gattermann MW Deininger RT Silver JM Goldman RM Stone, et al. 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 23 2408 2417 10.1056/NEJMoa062867 1:CAS:528:DC%2BD28Xht12ntrzM 17151364 (Pubitemid 44903745)
6. GD Demetri M von Mehren CD Blanke, et al. 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 7 472 480 10.1056/NEJMoa020461 1:CAS:528:DC%2BD38XmtV2nt7s%3D 12181401 (Pubitemid 34879334)
7. Holtkamp N, Okuducu AF, Mucha J et al (2006) Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis 27(3):664-671. Epub 2005 Dec 15
8. FC Yang DA Ingram S Chen, et al. 2008 Nf1-dependent tumors require a microenvironment containing Nf1+/-and c-kit-dependent bone marrow Cell 135 3 437 448 10.1016/j.cell.2008.08.041 1:CAS:528:DC%2BD1cXhtlyqtrzJ 18984156
9. DH Gutmann A Aylsworth JC Carey, et al. 1997 The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2 JAMA 278 1 51 57 10.1001/jama.278.1.51 1:STN:280:DyaK2szltV2lsQ%3D%3D 9207339
10. S Frahm VF Mautner H Brems, et al. 2004 Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients Neurobiol Dis 16 1 85 91 10.1016/j.nbd.2004.01.006 1:CAS:528:DC%2BD2cXjs1altLc%3D 15207265 (Pubitemid 38569799)
11. S Bihorel G Camenisch G Gross, et al. 2006 Influence of hydroxyurea on imatinib mesylate (gleevec) transport at the mouse blood-brain barrier Drug Metab Dispos 34 12 1945 1949 10.1124/dmd.106.010975 1:CAS:528:DC%2BD28Xht1yltLvL 16936068 (Pubitemid 44837753)
12. E Weisberg L Catley RD Wright, et al. 2007 (2007) Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL + leukemias Blood 109 5 2112 2120 10.1182/blood-2006-06-026377 1:CAS:528: DC%2BD2sXjtFequrc%3D 17068153 (Pubitemid 46348213)
13. D Babovic-Vuksanovic L Petrovic BE Knudsen TB Plummer JE Parisi S Babovic JL Platt 2004 Survival of human neurofibroma in immunodeficient mice and initial results of therapy with pirfenidone J Biomed Biotechnol 2004 2 79 85 10.1155/S1110724304308107 15240917 (Pubitemid 39281520)
14. JK Lee RA Sobel EA Chiocca TS Kim RL Martuza 1992 Growth of human acoustic neuromas, neurofibromas and schwannomas in the subrenal capsule and sciatic nerve of the nude mouse J Neurooncol 14 2 101 112 10.1007/BF00177613 1:STN:280:DyaK3s%2FlslKqsA%3D%3D 1432035
15. GQ Perrin L Fishbein SA Thomson, et al. 2007 Plexiform-like neurofibromas develop in the mouse by intraneural xenograft of an NF1 tumor-derived Schwann cell line J Neurosci Res 85 6 1347 1357 10.1002/jnr.21226 1:CAS:528: DC%2BD2sXlsV2rsLc%3D 17335073 (Pubitemid 46724377)
16. EA Lasater WK Bessler LE Mead, et al. 2008 Nf1+/- mice have increased neointima formation via hyperactivation of a gleevec sensitive molecular pathway Hum Mol Genet 17 15 2336 2344 10.1093/hmg/ddn134 1:CAS:528:DC%2BD1cXoslCit7w%3D 18442999